Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering hit by currency woes and lower prices:

This article was originally published in Clinica

Executive Summary

Increased sales in volume terms at German company Schering's diagnostics division were not enough to compensate for lower prices and currency effects in the first half of 1998. Diagnostic sales fell 4% to DM737 million ($416 million), with sales of X-ray contrast media fell 1% to DM549 million. Sales of MRI products fell 13% to DM184 million, largely due to stock reductions by US partner, Abbott Laboratories. The Berlin-based company's total sales increased 4% to DM3,216 million, while net income rose 8% to DM307 million.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT083203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel